MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.745 (-6.791%)

Company Metrics

  • P/E 13.83
  • P/S 7.429
  • P/B 2.133
  • EPS -1.284
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / 0%
  • Avg. Vol. 540,619.00
  • Shares 68.35M
  • Market Cap. 698.91M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2015 Results ... - Seeking Alpha
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Median Target At $18
Markets Daily - 23 hours ago
The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has 1-year target price of $18 while the median estimate is $18.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analyst Price Targets For The ...
Fiscal Standard - Jun 19, 2016
05/04/2016 - Momenta Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 18 price target on the stock.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Short Ratio At 9.24 - Vanguard Tribune
Momenta Pharmaceuticals Inc.: Momenta Pharmaceuticals Appoints Steven C ...
The Wall Street Transcript - Jun 23, 2016
CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C.
Why Momenta Pharmaceuticals, Inc. Was Up Today
Motley Fool - Jan 8, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) was up as much as much as 11.7% today, eventually finishing up 6.8% after announcing a deal with Mylan (NASDAQ:MYL) to develop six biosimilar products.
Momenta, Mylan to Jointly Develop Six Biosimilars - Wall Street Journal
Mylan to collaborate with Momenta to develop biosimilar products in $245M deal - Pittsburgh Business Times (blog)
Were Analysts Bearish Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) This Week?
Engelwood Daily - 16 hours ago
Out of 10 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Stock Momentum at Critical ...
CML News - Jun 22, 2016
Momenta Pharmaceuticals Inc. has a three bull (inflection point) technical rating because it's trading below both its 10 day and its 200 day simple moving averages.
It Seems Momenta Pharmaceuticals, Inc. Will Go Up. Have Another Big Increase - Franklin Independent
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Yearly Sales Projections At $305.705 - Investor Newswire
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ...
GlobeNewswire (press release) - May 19, 2016
CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of ...
How Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) trades after earning announcements?
Zergwatch - Jun 15, 2016
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) is expected to announce second quarter financial results estimated on July 28, 2016.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Yearly Sales Estimate At $305.705 - Investor Newswire